Lisa Aniek de Jong (Lisa A de Jong, Lisa de Jong, L A de Jong)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Venues

PharmacoEconomics

PloS one

Journal of medical economics

Journal of medical Internet research

University of Groningen

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Groningen Mar 01 2018

Netherlands

PhD Candidate Health Economics :: PharmacoTherapy, -Epidemiology and -Economics (PTEE)

Publications

Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma, Lisa Aniek de Jong
Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis. PloS one 19 (5) (2024)
Lisa Aniek de Jong, Xinyu Li, Sajad Emamipour, Sjoukje van der Werf, Maarten J Postma, Peter Ruben van Dijk, Talitha L Feenstra
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data. PharmacoEconomics 42 (9) (2024)
Lisa Aniek de Jong, Xinyu Li, Sajad Emamipour, Sjoukje van der Werf, Maarten J Postma, Peter Ruben van Dijk, Talitha L Feenstra
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data. PharmacoEconomics (2024)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan, Maarten Jacobus Postma, Lisa Aniek de Jong
Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis. PloS one 19 (5) (2024)
Lisa Aniek de Jong, Xinyu Li, Sajad Emamipour, Sjoukje van der Werf, Maarten J Postma, Peter Ruben van Dijk, Talitha L Feenstra
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data. PharmacoEconomics 42 (9) (2024)
Lisa Aniek de Jong, Xinyu Li, Sajad Emamipour, Sjoukje van der Werf, Maarten J Postma, Peter Ruben van Dijk, Talitha L Feenstra
Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data. PharmacoEconomics 42 (9) (2024)
Tanja Fens, Lisa Aniek de Jong, Bregt Kappelhoff, Cornelis Boersma, Maarten Jacobus Postma
Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran. Journal of market access & health policy 11 (1) (2023)
Sharon Wolters, Lisa Aniek de Jong, Christel Jansen, Frank Ga Jansman, Maarten J Postma
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European Health technology assessment bodies - can alignment be improved? Expert review of pharmacoeconomics & outcomes research (2023)
Robbert Bakema, Daria Smirnova, Despina Biri, Janwillem W H Kocks, Maarten Jacobus Postma, Lisa Aniek de Jong
The Use of eHealth for Pharmacotherapy Management With Patients With Respiratory Disease, Cardiovascular Disease, or Diabetes: Scoping Review. Journal of medical Internet research 25 (2023)
Lisa Aniek de Jong, Xinyu Li, S Emamipour, Sjoukje van der Werf, M J Postma, Peter Ruben van Dijk, Talitha L Feenstra
Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality. PharmacoEconomics - open (2023)
Jeroen H J Paulissen, Ahmed H Seddik, Kyle J Dunton, Christopher J Livings, Marinus H van Hulst, Maarten Jacobus Postma, Lisa Aniek de Jong, Roel D Freriks
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland. The European journal of health economics : HEPAC : health economics in prevention and care (2023)
Lisa Aniek de Jong, Alexander Victor van Schoonhoven, Hinko Stephan Hofstra, Maarten Jacobus Postma, Bart van Hoek
Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands. Journal of medical economics 24 (1) (2021)
Lisa Aniek de Jong, Annette W G van der Velden, Marinus van Hulst, Maarten J Postma
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. BMJ open 10 (11) (2020)
Lisa Aniek de Jong, Jessie Groeneveld, Jelena Stevanovic, Harrie Rila, Robert G Tieleman, Menno V Huisman, Maarten J Postma, Marinus van Hulst
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PloS one 14 (9) (2019)
Lisa Aniek de Jong, Judith J Gout-Zwart, Marina van den Bosch, Mike Koops, Maarten Jacobus Postma
Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis. Journal of medical economics 22 (4) (2019)

Lisa Aniek de Jong.css-eqlu8i{font-size:small;padding-left:4px;} (Lisa A de Jong, Lisa de Jong, L A de Jong)

Publication Activity (10 Years)

Top Topics

Top Venues

Lisa Aniek de Jong (Lisa A de Jong, Lisa de Jong, L A de Jong)